The US Food and Drug Administration has approved TNKase (tenecteplase), a thrombolytic or clot-dissolving agent, for the treatment of acute ischemic stroke in adults.

Intra-arterial thrombolysis via urokinase following reperfusion by endovascular thrombectomy for stroke does not affect survival without disability.

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Protagonist Therapeutics (PTGX – Research Report) and Roche ...

Individuals with high PLMs had significantly higher Fazekas and ARWMC total scores than those with a lower PLM index.